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University of British Columbia, Vancouver, BC, CanadaA B S T R A C TBackground: The recent Global Initiative for Asthma management
strategy recommends achieving symptom control and minimizing the
future risk of poor outcomes as priorities for asthma management.
Objective: The objective was to quantify the association between
symptom control and health-related quality of life in asthma.
Methods: In a prospectively recruited random sample of adults with
asthma, we ascertained symptom control and measured health-
related quality of life using a generic (EuroQol ﬁve-dimensional
questionnaire [EQ-5D]) and a disease-speciﬁc (Asthma Quality of Life
Questionnaire) instrument, to estimate EQ-5D and ﬁve-dimensional
Asthma Quality of Life Questionnaire (AQL-5D) utilities, respectively.
We measured the adjusted difference in utilities across symptom
control levels and calculated the loss of predictive efﬁciency due to
aggregating multiple symptoms into one symptom control variable.
Results: The ﬁnal sample included 958 observations from 494 indi-
viduals (mean age at baseline 52.2  14.5 years; 67.0% women).
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ancouver, BC, Canada V5Z 1M9.uncontrolled in 269 (28.1%), 367 (38.3%), and 322 (33.6%) observations,
respectively. A person with symptomatically uncontrolled asthma
would gain 0.0512 (95% CI 0.0339–0.0686) in EQ-5D or 0.0802 (95% CI
0.0693–0.0910) in AQL-5D utilities by achieving symptom control. The
loss of predictive efﬁciency was 55.4% and 27.6% for EQ-5D and AQL-5D
utilities, respectively. Conclusions: Asthma symptom control status
corresponds well with both generic and disease-speciﬁc quality-of-life
measures. The trade-off, however, between ease of use and predictive
power should be reconsidered in developing simpliﬁed measures of
control. Our results have direct relevance in informing decision-
analytic models of asthma and deducing the effect of interventions
on quality of life through their impact on asthma control.
Keywords: asthma, observational studies, quality of life, regression
analysis.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Impairment due to asthma can have a substantial impact on
quality of life [1]. Because there are no realistic options to
completely prevent or cure asthma, the emphasis of current
asthma management guidelines is to control the manifestations
of the disease [2,3]. One of the most widely used measures of
asthma control is the deﬁnition developed by the Global Initiative
for Asthma (GINA). In the most recent version of the GINAmanagement strategy, assessment of asthma control is divided
into assessing symptom control and risk factors for future poor
asthma outcomes [4]. This is a departure from the previous GINA
strategy, which included both symptoms and lung function
metrics in the deﬁnition of clinical control [5].
Given the central role of asthma control as a framework for
the management of asthma, guidelines have emphasized the use
of asthma control as a relevant outcome both in clinical practice
and in research [3]. From a policy perspective, however,ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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ping the causal relationships between asthma control and policy-
relevant outcomes such as costs and quality of life. Estimating
the impact of interventions on health-state utility values (util-
ities) enables quantiﬁcation of their health impact in terms of
quality-adjusted life-year (QALY) as the metric of choice for cost-
effectiveness studies [6]. As such, estimates of change in utility as
a result of change in asthma control can be of value in informing
decision-analytic models of asthma.
Developing simple and easy-to-use measures of asthma con-
trol involves aggregating different metrics to calculate one or
more global scores. In the case of GINA symptom control, the four
domains with binary (yes/no) responses create 16 permutations,
which are then reduced to a three-level symptom control varia-
ble. Such an aggregation inevitably results in loss of information.
Evaluating the impact of information loss in terms of the
efﬁciency of the GINA deﬁnition of symptom control in predicting
policy-relevant outcomes will help researchers reﬁne such meas-
ures. In the present study, we investigated such issues using the
2014 GINA deﬁnition of asthma symptom control as it relates to
quality of life. The primary objective of this study was to quantify
the gain in quality of life that can be achieved by achieving GINA
symptom control in patients with symptomatically uncontrolled
or partially controlled asthma. We pursued several secondary
objectives: to estimate the loss of predictive efﬁciency by aggre-
gating four symptom domains into a single symptom control
variable, to evaluate the relative inﬂuence of individual symptom
domains on quality of life, and to evaluate the impact of the
removal of lung function measurement in the recent GINA
deﬁnition on its association with quality of life.Methods
Study Population
This study was based on data from the Economic Burden of
Asthma, a prospective observational study aimed at measuring
the economic and humanistic burden of asthma at the popula-
tion level (University of British Columbia Human Ethics no. H10-
01542). Details about the study have been described elsewhere
[7,8]. Through random digit dialing in two census areas in British
Columbia, Canada, the study recruited 618 individuals with self-
reported, physician-diagnosed asthma. The census areas con-
sisted of the Metro Vancouver and Okanagan regions (2011
populations of 603,502 and 179,830, respectively [9]); these areas
were chosen to represent both urban and rural populations.
Eligibility criteria also included having had at least one asthma-
related encounter with the health care system in the past 5 years,
not being pregnant or planning to become pregnant in the next 12
months, and planning to reside in the study area for the next 12
months. The follow-up time was 12 months, with visits sched-
uled every 3 months. At baseline and ﬁnal visits, individuals
underwent spirometry and responded to an asthma symptoms
questionnaire, permitting the evaluation of asthma control
according to both 2012 and 2014 GINA guidelines [2]. The ﬁnal
visit was generally around 1 year after entry; however, for
participants who notiﬁed the investigators of their withdrawal,
spirometry was performed in their last visit before withdrawal.
The subsample for the present study included adults in whom
both asthma control and quality of life had been measured at ﬁrst
and/or last visits.
Exposure
The main exposure was symptom control as deﬁned by the 2014
GINA management strategy [4]. This deﬁnition is based on fourdomains, which focus on outcomes from the past 4 weeks, each
taking a binary value (no ¼ 0, yes ¼ 1): daily symptoms (two or
less vs. more), limitations of activities (none vs. any), nocturnal
symptoms/awakening (none vs. any), and need for reliever or
rescue treatment (two or fewer vs. more). The previous (2012)
GINA management strategy deﬁned clinical control (as opposed
to symptom control) on the basis of the same symptom domains
plus a ﬁfth domain that is the ratio of forced expiratory volume in
1 second (FEV1) to its predicted value (cutoff 80%) [5]. For the sake
of brevity, we use the term control to refer to clinical control or
symptom control, respectively, whenever the 2012 or 2014 ver-
sions of GINA management strategies are considered. In both
versions, asthma is deﬁned as uncontrolled if three or more of
the domain values are positive, partially controlled if one or two
values are positive, and controlled otherwise.
Outcomes
Individuals at baseline and all follow-up visits ﬁlled out a generic
preference-based instrument (EuroQol ﬁve-dimensional ques-
tionnaire [EQ-5D], three-level version [10]), as well as the short
version of the Asthma-related Quality of Life Questionnaire
(mini-AQLQ [11]). We used the National Health and Nutrition
Examination Survey reference standards for estimating predicted
FEV1 values [12]. Both EQ-5D and AQLQ responses were converted
to health-state utility values (utilities). To derive EQ-5D utilities,
we used the algorithm as described by Dolan et al. [13]. For AQLQ,
we followed the two-step approach as described by Yang et al.
[14]: ﬁrst, the response levels were reduced from seven to ﬁve as
proposed in Young et al. [15] and then the algorithm proposed by
Yang et al. [14] was used to calculate ﬁve-dimensional Asthma
Quality of Life Questionnaire (AQL-5D) utilities. Given that the
latter weight is based on a UK sample, we also used UK tariffs for
the EQ-5D to ensure comparability [13].
Statistical Analysis
All statistical analyses were performed in SAS (version 9.3, Carey,
NC). Two-tailed P values at the 0.05 level were evaluated for
statistical signiﬁcance. The unit of observation in this study was
a study visit resulting in concomitant assessment of both utilities
and asthma control. Chi-square test for categorical variables and
analysis of variance for continuous variables were used to
examine the distribution of variables across control levels.
Adjusted analyses were based on ﬁtting regression models
that would associate utilities with asthma control, adjusting for
potential confounding variables. Given that a proportion of
individuals would report a utility value of 1, the assumptions of
normally distributed regression residuals, required for inference
in the conventional ordinary least squares (OLS) regression,
would not be satisﬁed. We therefore used a two-part regression
model, with logistic and OLS components [16]. The logistic
component was ﬁtted to model the impact of independent
variables on the probability of having a utility of 1, and an OLS
regression was ﬁtted in the subset of individuals with a utility of
less than 1 to model the linear effect of independent variables on
utility values. We used generalized linear models with general-
ized estimating equations for both components to account for the
clustering of observations (visits) within individuals [17]. The
three-level GINA control variable entered the model as two
dummy variables representing partially controlled and uncon-
trolled asthma with the reference being controlled asthma.
Inference was made using parametric bootstrapping with 100
replications. For both components, we chose the following
covariates as potential confounders: age at baseline visit, sex,
income (high vs. low at the cutoff of Can $60,000 per year), edu-
cation level (high [postsecondary education or higher] vs. low),
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urban), and insurance coverage for medications (complete vs.
partial vs. no coverage).
Primary Objective—the Relationship between Symptom
Control and Quality of Life
The adjusted “marginal” effect of symptom control on utilities
was recovered by combining regression coefﬁcients from the
logistic and OLS parts using G-computation [16,18]. G-
computation operates by calculating the predicted values from
both regression components, thus enabling the calculation of the
expected utility under a given exposure level (uncontrolled,
partially controlled, or controlled asthma) for each individual in
the sample. Marginal values are recovered by averaging the
predicted utilities within each level of control across the sample
[18]. Provided that there are no unmeasured confounders, the
marginal estimates can be interpreted causally as the expected
change in utility by achieving control for a random subject with
uncontrolled (or partially controlled) asthma.
We performed additional sensitivity analyses. We repeated the
analysis by restricting the data to ﬁrst visit as well as to the last
visit. In addition, the subsample of individuals who had different
asthma control status in at least two visits provides an alternative
opportunity of estimating change in utility. We ﬁtted a separate
two-part model for this subsample with change in utility as the
dependent variable and change in asthma control as the inde-
pendent variable to estimate the effect of change in asthma
control on utilities from this “within-individual” design [19].
Secondary Objectives
Predictive Efﬁciency of GINA Deﬁnition of Symptom Control
We investigated the predictive power (for predicting utilities) lost
by aggregating the four symptom domains into a single symptom
control variable. This was performed by comparing the coefﬁcient
of determination (R2), the ratio of variance of utility explained byTable 1 – Demographic characteristics of the sample acro
Variable All
n ¼ 9
Controlled
n ¼ 69
Age (y), mean  SD 52.36  14.47 53.04  15.01
Sex (%)
Male 32.9 40.5
Female 67.1 59.5
Income (%)
Low 57.1 47.2
High (460K/y) 42.9 52.8
Education (%)
Low 24.5 28.3
High 75.5 71.7
Place of birth (%)
Canada 70.8 70.3
Foreign born 29.2 29.7
Residence type (%)
Urban 91.0 92.2
Rural 9.0 7.8
Insurance for medications
(%)
None 15.4 19.3
Partial 63.2 58.7
Complete 19.2 17.1
* The unit of observation is study visits.the model over the total variance [20], for three two-part models
for utilities (separately for the EQ-5D and the AQL-5D). Model 1
included only covariates, model 2 included covariates and GINA
symptom control, and model 3 included covariates plus four
symptom domains and their ﬁrst-order interaction terms. We
deﬁned the loss of efﬁciency as follows:
Loss of efficiency¼ R2 of model 3–R2 of model 2 =
R2 of model 3–R2 of model 1
 
The numerator is the gain in R2 that would have been
achieved by using full range of symptom domains compared
with using the GINA symptom control, and the denominator is
the maximum possible gain in R2; thus, the ratio will be between
0 and 1 and can be presented in percentage.
Relationship between Symptom Domains and Utilities
We created a reference two-part model with covariates and
symptom domains and their ﬁrst-order interaction as predictors
(similar to model 3). From this model, we estimated the reduction
in R2 when a particular symptom domain is removed from the
model. The most inﬂuential symptom domain is the one whose
removal results in the largest drop in R2.Results
A total of 496 adults contributing 961 observations with asthma
were eligible for this study. Three study visits were excluded
because symptoms or lung function were not properly recorded.
The ﬁnal sample consisted of 958 observations from 494 unique
individuals. Mean age at baseline was 52.2  14.5 years; women
comprised 67.0% of the sample. Table 1 presents the baseline
characteristics of observations in total as well as within symptom
control levels. Recruitment occurred between January 2011 and
July 2012. The average time between the ﬁrst and ﬁnal visits
was 375.1 days (range 185–485; 5th–95th percentile 349–426).ss study visits, according to the level of control*.
Partially controlled
n ¼ 367
Uncontrolled
n ¼ 22
P
51.41  14.64 52.89  13.78 o0.01*
o0.01*
34.3 24.8
65.7 75.2
0.01*
42.0 53.4
58.0 46.6
0.20
22.1 24.2
77.9 75.8
71.7 70.2 0.89
28.3 29.8
o0.01*
93.7 87.0
6.3 13.0
0.17
14.2 13.7
65.1 64.6
18.5 21.7
Table 2 – Utility scores across and within visits.
Visit Mean  SD (n) P
All Controlled Partially controlled Uncontrolled
EQ-5D
Both visits 0.916  0.129 (n ¼ 958) 0.945  0.097 (n ¼ 269) 0.922  0.127 (n ¼ 367) 0.884  0.146 (n ¼ 322) o0.001*
First visit 0.908  0.125) (n ¼ 494) 0.936  0.095 (n ¼ 127) 0.916  0.121 (n ¼ 194) 0.878  0.141 (n ¼ 173) o0.001*
Last visit 0.924  0.133 (n ¼ 464) 0.952  0.098 (n ¼ 142) 0.928  0.133 (n ¼ 173) 0.891  0.153 (n ¼ 149) o0.001*
Difference 0.015  0.006 0.019  0.008 0.009  0.011 0.014  0.013 o0.001*,†
AQL-5D‡
Both visits 0.927  0.077 0.969  0.045 0.935  0.065 0.884  0.088 o0.001*
First visit 0.924  0.081 0.970  0.047 0.934  0.068 0.880  0.091 o0.001*
Last visit 0.930  0.073 0.968  0.043 0.935  0.063 0.889  0.084 o0.001*
Difference 0.006  0.003 –0.001  0.004 –0.002  0.006 0.008  0.008 o0.001*,†
* Signiﬁcant at the 0.05 level.
† Represents the statistical signiﬁcance of change between ﬁrst and last visits in utilities across control groups.
‡ Numbers of observations are similar to the corresponding values in the top half of the table.
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asthma, represented by a low rate of asthma-related emergency
department visits (10.7%) or hospitalizations (4.0%) in the year
before enrollment. In 269 (28.1%), 367 (38.3%), and 322 (33.6%) visits,
asthma was symptomatically controlled, partially controlled, or
uncontrolled, respectively. The distribution of several baseline
variables was signiﬁcantly different across control levels (Table 1).
Table 2 presents the unadjusted comparison of utility scores
across symptom control groups, separately within the ﬁrst and
last visits, as well as for both visits combined. In all comparisons,
the difference in both EQ-5D and AQL-5D utility scores across
control levels was statistically signiﬁcant, with a gradient of
decreasing mean utility values with less controlled asthma.
Across all visits, 531 (55.4%) of EQ-5D and 189 (19.7%) of AQL-5D
values were 1. Distribution of EQ-5D and AQL-5D domains across
symptom control levels is provided in Supplemental Material
found at http://dx.doi.org/10.1016/j.jval.2015.07.008.
Primary Outcome
Table 3 provides results of the two-part regression model relating
symptom control to EQ-5D and AQL-5D utility scores. There was a
signiﬁcant reduction for symptomatically uncontrolled compared
with symptomatically controlled asthma in both EQ-5D (differ-
ence –0.0512; 95% conﬁdence interval [CI] –0.0686 to –0.0339) and
AQL-5D (difference –0.0802; 95% CI –0.0910 to –0.0693) utilities.Table 3 – Change in utility by change in level of control:
Variable
Partially controlled (vs. controlled)
Adjusted odds ratio for reporting perfect utility
Adjusted utility loss for those who reported imperfect utility
Adjusted loss of utility
Uncontrolled (vs. controlled)
Adjusted odds ratio for reporting perfect utility
Adjusted utility loss for those who reported imperfect utility
Adjusted loss of utility
* Signiﬁcant at the 0.05 level.Similarly, for partially controlled asthma, there was a signiﬁcant
reduction for both EQ-5D (difference –0.0217; 95% CI –0.0344 to –
0.0089) and AQL-5D (difference –0.0337; 95% CI –0.0430 to –0.0243)
utilities. Regression coefﬁcients for independent variables are
provided in Supplemental Material found at http://dx.doi.org/10.
1016/j.jval.2015.07.008.
Results of sensitivity analyses are provided in Supplemental
Material found at http://dx.doi.org/10.1016/j.jval.2015.07.008. Lim-
iting the observations to only the ﬁrst visit or the ﬁnal visit did
not substantially change the results. However, the difference in
utilities across control levels was smaller in the within-individual
analysis. The change in utilities from uncontrolled to controlled
asthma was 0.0285 for the EQ-5D utility (P ¼ 0.10) and 0.0278 for
the AQ-5D utility (P o 0.01). The corresponding values for change
from partially controlled to controlled asthma were 0.0023 (P ¼
0.88) and 0.0199 (P ¼ 0.02), respectively.
Secondary Objectives
Predictive Efﬁciency of GINA Deﬁnition of Symptom Control
The regression model that included only covariates could explain
8.8% and 10.3% of the variation in the EQ-5D and the AQL-5D,
respectively. The addition of GINA control variable increased this
to 11.5% and 27.3%, respectively. The model with individual
symptom domains, however, increased the explained variation to
14.9% for EQ-5D and 33.8% for AQL-5D utilities. As such, the loss ofEffect (95% conﬁdence interval).
EQ-5D AQL-5D
0.69 (0.49–0.97)
P ¼ 0.032*
0.27 (0.18–0.39)
P o 0.001*
–0.0214 (–0.0495 to 0.0067)
P ¼ 0.135
–0.0273 (–0.0370 to –0.0175)
P o 0.001*
–0.0217 (–0.0344 to –0.0089)
P o 0.01*
–0.0337 (–0.0430 to –0.0243)
P o 0.01*
0.48 (0.33–0.70)
P o 0.001*
0.12 (0.07–0.20)
P o 0.001*
–0.0445 (–0.0755 to –0.0136)
P ¼ 0.135
–0.0705 (–0.0838 to –0.0573)
P o 0.001*
–0.0512 (–0.0686 to –0.0339)
P o 0.01*
–0.0802 (–0.0910 to –0.0693)
P o 0.01*
Table 4 – Variance components (R2).
Independent variables* EQ-5D (%) AQL-5D (%)
Covariates only 8.8 10.3
Covariates þ GINA 2014
(symptom) control variable
11.5 27.3
Covariates þ individual
symptom domains
14.9 33.8
Efﬁciency loss 55.4 27.6
Proportion of variance explained when GINA 2014 domain
variables are removed
Covariates þ individual
symptom domains except
daily symptoms
14.8 33.1
Covariates þ individual
symptom domains except
limited activities
11.1 24.6
Covariates þ individual
symptom domains except
nocturnal symptoms
13.7 31.0
Covariates þ individual
symptom domains except
need for reliever
14.8 33.3
Proportion of variance explained with 2012 GINA deﬁnition of
clinical control
Covariates þ GINA 2012
(clinical) control variable
11.1 27.2
AQL-5D, ﬁve-dimensional Asthma Quality of Life Questionnaire;
EQ-5D, EuroQol ﬁve-dimensional questionnaire; GINA, Global
Initiative for Asthma.
* All numbers are R2 from the two-part model (ratio of explained
variance to total variance), with the exception of efﬁciency loss,
whose deﬁnition is provided in the text.
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for EQ-5D and 27.6% for AQL-5D utilities (Table 4, top section).
Relationship between GINA Symptom Domains and Quality of
Life
The middle section of Table 4 demonstrates the inﬂuence of
individual symptom domains on explaining the variation in EQ-
5D and AQL-5D utilities. For both, the domain with the largest
inﬂuence was limited activities. The inﬂuences of three other
domains on explaining the variance of utilities were lower but
were similar with each other.
The Impact of removing FEV1 from the Deﬁnition of Asthma
Control
When the 2012 GINA deﬁnition of asthma control was applied to
the study sample, in 183 (19.1%), 400 (41.8%), and 375 (39.1%)
observations, asthma was categorized as being controlled, parti-
ally controlled, and uncontrolled, respectively. Compared with
the 2014 GINA symptom control deﬁnition, the use of 2012 GINA
asthma control variable reduced the R2 from 11.5% to 11.1% for
EQ-5D and from 27.3% to 27.2% for AQL-5D utilities (Table 4,
bottom section).Discussion
We performed a detailed analysis of the association between
symptom control levels as deﬁned in 2014 GINA management
strategy with quality of life in a random sample of patients with
asthma. We estimated that by achieving symptom control in a
patient with symptomatically uncontrolled asthma, a gain of0.0512 in EQ-5D and 0.0802 in AQL-5D utilities could be achieved.
Assuming that we have adequately adjusted for confounding
variables, the reported change in utilities across control levels
can directly be used in decision-analytic models of asthma that
use GINA-deﬁned asthma control as their core disease states. We
also showed that aggregating individual symptom domains into a
single symptom control variable is associated with substantial
loss of predictive power especially when EQ-5D utilities are
concerned. Among the four symptom domains, limitation in
activities was mostly correlated with quality of life. Finally, we
showed that as long as quality of life is concerned, relocating
lung function metrics from symptom control to risk factors for
worse outcomes in the latest GINA recommendations seems
justiﬁable.
In the sensitivity analysis that estimated the difference
between utilities from within-individual observation pairs, esti-
mates were smaller, and for EQ-5D utilities they were not
statistically signiﬁcant. This can be interpreted as this analysis
being more robust than the main analysis in controlling for
unmeasured time-ﬁxed confounders. Within-individual studies,
however, are subject to other threats to validity such as carry-
over, recall, and demand (prevarication) biases [21]. First, the
sample that experienced different levels of control between the
ﬁrst and last visits does not constitute a random sample of the
target population. In addition, in this particular context, individ-
uals’ assessment of asthma control and utility values can be
affected by their recall of previous responses, resulting in dilution
of regression coefﬁcients. Also, GINA asthma control is an
aggregate measure and individuals could still vary within a given
level. Therefore, the magnitude of within-individual changes in
symptom control between the two visits might have been more
limited than the difference between two independent visits. A
post hoc analysis of the data indicated the presence of such
phenomena. The average number of present symptoms was
3.17 (out of 4) in instances of uncontrolled asthma that had a
paired controlled asthma status, whereas this value was 3.53 for
all other instances of uncontrolled asthma. Overall, we believe
that given both exposure and outcomes are subjectively assessed,
within-individual designs might be susceptible to bias, and our
main analysis that uses all observations based on a model for the
full data is a more robust approach, provided that it has
sufﬁciently accounted for confounding factors.
To our knowledge, this is the ﬁrst study of the association
between asthma symptom controls, as deﬁned by the latest GINA
management strategy, and utilities. Previous studies have
reported on the association between various measures of asthma
control and quality of life [1,22–30], but for the most part the
authors did not use utilities for quality of life; thus, quantiﬁcation
of the outcome in terms of QALYs was not possible. Also, many
studies simply reported average utility scores across control
levels. Although informative, these unadjusted results can be
confounded by factors that affect quality of life and asthma
control, and thus cannot be causally interpreted. Two exceptions
are the studies by Chen et al. [1] and Briggs et al. [29]. In the
former study, after adjusting for several potential confounding
variables, asthma control as deﬁned by the Asthma Therapy
Assessment Questionnaire [31] had a clear dose-response asso-
ciation with EQ-5D utilities. In Briggs et al. [29], the association
between asthma control levels, as deﬁned similarly to previous
GINA deﬁnitions, and AQLQ-derived utilities was evaluated using
the data of a large randomized trial [29]. Randomization on
treatment does not protect against the confounding effect of
factors affecting asthma control and quality of life, and the
regression model was not adjusted for important confounders
such as sex or socioeconomic status, but the association was
controlled for asthma severity in terms of the intensity of treat-
ment in the run-in period [29].
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associated with AQL-5D scores as disease-speciﬁc utilities is not a
surprise given that they are both based on asthma-related impair-
ment. However, the fact that limitation in activities is the stron-
gest predictor is worthy of consideration. Both exposure and
outcome assessment instruments (GINA symptom control, EQ-
5D, and AQLQ) have items concerning activity limitations, and this
might have resulted in strong correlations around activity limi-
tation. The magnitude of explanatory power attributed to each
component of asthma control is, in part, a function of character-
istics of the instrument selected as the dependent variable, and
not necessarily reﬂective of the underlying construct. Utilities
estimated using more robust methods such as standard gamble
or time trade-off can provide better insights in this regard.
Currently, all variables are given the same weight as daytime
and nocturnal symptoms and need for relievers, but a deﬁnition
that assigns more weight to variables that are more strongly
associated with quality of life can potentially improve the
correlation of symptom control with quality of life and reduce
the loss of predictive power. Whether such a gain in efﬁciency is
acceptable at the cost of increased complexity requires further
considerations. However, it can be argued that a robust measure
of control should correlate well with not only quality of life but
also resource use and costs. Nevertheless, with the separation of
the risk of future adverse outcomes, which most likely determine
costs, from symptom control in the recent GINA deﬁnition, we
argue that the association of symptom control with quality of life
is the most relevant metric for its performance, thus justifying
attempts to improve the predictive power of symptom control
with respect to quality of life.
The limitations of our study should be considered. First,
scoring functions for both the EQ-5D and the AQL-5D are derived
on the basis of responses from the UK population; as a result,
they may differ from the preferences of the Canadian population.
Our EQ-5D scores and associated utility values were higher than
those of the normative values (UK population) [32] as well as the
recently reported Canadian values [33], despite the fact that
individuals in our study sample had asthma to begin with. A
likely reason for this phenomenon is the healthy volunteer bias
associated with a clinical study in which participants had to
attend the study sites multiple times. Given the likely broader
range of the distribution of quality of life in the general asthma
population and the higher level of morbidity, our results might be
an underestimate of the effect of asthma control on quality of life
(i.e., the gain in quality of life with improving asthma control
would likely be larger in the general population than in our study
sample). Another limitation is that, due to overlap in some of the
questions between GINA, the EQ-5D, and the AQL-5D, recall bias
might have played a role in creating a positive correlation. Direct
elicitation of utilities using standard gamble or time trade-off can
overcome this potential bias. In addition, our study was restricted
to the four symptom domains included in the deﬁnition of GINA
symptom control. There might be other symptom domains or
variables whose inclusion in the assessment of asthma control
can further enhance its association with quality of life. This
remains to be studied in the future.
We particularly designed our study such that results can
inform decision-analytic models of asthma that predict longitu-
dinal transition across control levels. We did not adopt a
longitudinal design (associating baseline control and follow-up
utilities) because the interest was in the magnitude of association
between current control level and utility. This is required for
decision-analytic models of asthma that assign utility values to
asthma control states. The longitudinal design, although more
robust in drawing causal estimates between control and utility,
would underestimate the quantity of interest because of the
contamination of exposure groups (due to within-individualchanges in control over time) as described in Hernan et al. [34].
Another important consideration in this regard is that none of
our study participants at any of the study visits reported expe-
riencing an exacerbation of asthma. As such, the estimated gain
in utilities from this analysis does not include the gain associated
with a lower rate of exacerbations when asthma is better
controlled. We do not see this as a drawback of our study.
Decision-analytic models of asthma often explicitly incorporate
exacerbations and associated reduction in quality of life [29];
thus, the utility values across control levels should exclude the
effect of exacerbations as well in order to be informative to such
models.
In many jurisdictions, the prevalence of poorly controlled
asthma is high [35]. However, the conventional wisdom is that
with proper management, asthma control can be achieved in
most of the patients [36]. Given that inexpensive and effective
treatments are available for this purpose, uncontrolled asthma
represents a gap in care and a preventable source of burden. We
speciﬁcally showed that efforts in achieving symptom control
can be associated with signiﬁcant gain in quality of life. In
addition, our study points out toward potentials for improvement
in the assessment tools for asthma control. Designing measure-
ment tools that can correlate well with policy-relevant outcomes
can enhance our abilities to provide efﬁcient care and design and
implement efﬁcient interventions for the management of
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